What we do Senores Pharmaceuticals Limited develops and manufactures specialty and complex pharmaceutical products for regulated markets including the US and Canada, and emerging markets globally. |
Founded in 2,017 |
Market share Holds 46 ANDA approvals, with a strong presence in regulated and emerging pharmaceutical markets across 43 countries. |
Problem solved Addresses critical drug shortages and unmet needs via niche, underpenetrated and complex formulations in multiple therapeutic areas. |
Top clients or who we serve Serves pharmaceutical companies in regulated markets (US, Canada) and distributors in emerging markets; operates B2B and B2C business models. |
Key management Swapnil Jatinbhai Shah (Managing Director), Deval Rajnikant Shah (Whole-Time Director & CFO), Chetan Bipinchandra Shah (Whole-Time Director & COO) with 15+ years pharmaceutical expertise. |
Our journey and innovations Incorporated in 2017; expanded via acquisitions (Havix, Ratnatris, Apnar Pharma); launched greenfield API plant; IPO raised Rs 582 Crore in 2024. |
Where we operate Operates in India and 43+ countries globally including US, Canada, UK, emerging markets across Asia, Africa, Latin America, and Middle East. |
Top products or what we offer Offers specialty ANDAs for regulated markets, branded generics for emerging markets, critical care injectables in India, and active pharmaceutical ingredients (APIs). |
Top brands Regulated Markets ANDAs (46 approved), Critical Care Injectables, API products, and Emerging Markets branded generics with 450+ products registered. |
Raw materials needed Pharmaceutical-grade APIs, chemical intermediates for drug formulations and injectables. |
Raw materials supplier Sources from global and domestic suppliers, including acquisitions that bring backward integration like Ratnagene Lifescience. |
Recurring vs cyclical contribution Revenue is largely recurring from pharmaceuticals manufacturing, licensing, and long-term marketing agreements. |
Our industry position Rapidly growing niche player with a strong regulated market pipeline and expanding emerging markets footprint; 92% consolidated revenue growth in FY25. |
Financial highlights FY25 consolidated revenue Rs 417.51 Cr, profit Rs 58.34 Cr; standalone revenue Rs 60.53 Cr with 48% growth; strong EBITDA margins around 29-31%. |
Geographical revenue split FY25 revenue split: 74% outside India (Rs 293 Cr), 26% within India (Rs 105 Cr). |
Order book - |
Whats driving growth Growth driven by regulatory approvals (ANDAs), strategic acquisitions, increased market penetration, and expanding API and injectables manufacturing. |
Our future plans Expand US and Indian manufacturing capacity, complete Apnar Pharma acquisition, enhance CMO/CDMO capabilities, and increase regulated and emerging market product launches. |
Our green promise - |
Our people and values Employs over 104 staff in critical care injectables; professional management team with extensive pharmaceutical industry experience and commitment to ethical governance. |
Key challenges ahead Regulatory compliance, competition in generic pharmaceutical markets, integration of acquisitions, and managing working capital and expansion capex. |
Interesting facts Achieved consolidation with three subsidiaries, significant IPO raising Rs 582 Cr, rapid scale-up of ANDAs and product pipeline within five years of founding. |
Risks and strategy Risk mitigation via diversified product portfolio, backward integration, regulatory compliance, and strategic partnerships enhancing market access. |
